Novel mRNA-based Prognostic Index Derived from Differential Expression Analysis Improves Overall Survival Estimates in Glioblastoma

Case ID:
UA22-209
Invention:

This technology is a set of biomarkers to predict radiotherapy and chemotherapy outcomes in individual Glioblastoma Multiforme patients to better assess their prognosis and therapy.

Background:
Glioblastoma Multiforme (GBM) is the most aggressive form of brain cancer and is currently treated through surgical intervention, chemotherapy and radiotherapy. The effectiveness of chemotherapy and radiotherapy fluctuates depending on the patient. While some patients benefit from them, others do not see any positive effects. This technology is a set of biomarkers in Wnt signaling pathway and it provides a means of effectively predicting which patients will be long-term survivors after chemotherapy and radiotherapy. It can also potentially be used to predict patient responses to drugs that inhibit Wnt signaling pathway. 

Applications:

  • Prediction of chemotherapy and radiotherapy effectiveness in GBM patients
  • Companion diagnostic for inhibitors to Wnt pathway


Advantages:

  • Provides a more precise prediction of treatment outcomes
  • Avoids the use of unnecessary or excessive treatments
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
mitchg@tla.arizona.edu
Lead Inventor(s):
Eric Weterings
Baldassarre Stea
Daruka Mahadevan
Michael Hammer
Christopher Morrison
Keywords: